-
Bayer Partners with Google Cloud to Develop AI-Powered Medical Imaging Solutions
•
Germany’s pharmaceutical and life sciences giant Bayer (ETR: BAYN) has joined forces with US technology company Google Cloud (NASDAQ: GOOG) to develop artificial intelligence (AI) driven medical imaging solutions focused on radiology. This strategic collaboration aims to leverage patient data sets to create tools that alleviate the burden of repetitive…
-
Simcere Pharmaceutical’s SIM0500 Earns FDA Fast-Track Designation for Multiple Myeloma
•
Simcere Pharmaceutical Group (HKG: 2096), a leading China-based pharmaceutical company, has announced that its trispecific antibody SIM0500 has received fast-track designation from the US Food and Drug Administration (FDA) for the treatment of multiple myeloma (MM). The drug targets GPRC5D, BCMA, and CD3, and is intended for patients who have…
-
Roche’s Inavolisib Earns Priority Review Status in China for PIK3CA-Mutated Breast Cancer
•
Swiss pharmaceutical giant Roche (SWX: ROG) has received priority review status from China’s Center for Drug Evaluation (CDE) for its investigational drug inavolisib (GDC-0077), a phosphatidylinositol-3 kinase α (PI3Kα) inhibitor. The drug is being evaluated for the treatment of PIK3CA-mutated, hormone receptor (HR) positive, human epidermal growth factor receptor 2…
-
Sichuan Biokin Pharmaceuticals Initiates Phase III Trial for BL-M05D1 in Esophageal Cancer
•
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the commencement of patient enrollment in a Phase III clinical trial for its antibody-drug conjugate (ADC), BL-M05D1, in patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC). This milestone marks a significant advancement in the development of BL-M05D1, which targets…
-
Jiangsu Hengrui Medicine Advances Pipeline with NMPA Approvals for Three Drugs
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has received clinical trial approvals from China’s National Medical Products Administration (NMPA) for three of its pipeline drugs: HRS-9231, SHR-4597, and SHR-2173. This regulatory milestone marks a significant step forward in the company’s commitment to innovate and address unmet medical needs in China…
-
Apeloa Pharmaceutical Partners with Heze Pharmaceutical for Semaglutide Biosimilar Development
•
Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a prominent player in the Chinese pharmaceutical industry, has entered into a strategic partnership with Zhejiang Heze Pharmaceutical Technology Co., Ltd to co-develop a semaglutide biosimilar. While the financial terms of the agreement were not disclosed, the collaboration will encompass joint research and development…
-
Suzhou SmartNuclide Biopharmaceutical Secures $13.8 Million in Series C+ Funding to Advance Radiopharmaceutical Pipeline
•
Suzhou SmartNuclide Biopharmaceutical Co., Ltd, a leading developer of radiopharmaceuticals in China, has announced the completion of a Series C+ financing round worth RMB 100 million ($13.8 million). The round was led by Oriza Holdings, with significant contributions from YZ Capital, JianSu Capital, Leader Venture Capital, and returning investor RealHarmony…
-
Arnatar Therapeutics Secures $50 Million in Series A Funding to Expand into China
•
US-based biotechnology company Arnatar Therapeutics has successfully closed a $50 million Series A financing round, marking a significant step in the firm’s expansion plans into the Chinese market. The funding round, co-led by 3E Bioventures and Eight Roads, attracted substantial Chinese investment, highlighting the growing interest in innovative biotech solutions…
